CAMBRIDGE, Mass., Nov. 7, 2023
/PRNewswire/ -- Theseus Pharmaceuticals, Inc. (NASDAQ: THRX)
(Theseus or the Company), a clinical-stage biopharmaceutical
company focused on improving the lives of cancer patients through
the discovery, development, and commercialization of transformative
targeted therapies, today announced that the company will
participate in a fireside chat at the Stifel 2023 Healthcare
Conference on Tuesday, November 14 at
9:45 a.m. ET.
A live webcast of the fireside chat will be available in the
Events section of the company's investor relations website at
ir.theseusrx.com and archived for 30 days following the
presentation.
About Theseus Pharmaceuticals, Inc.
Theseus is a clinical-stage biopharmaceutical company focused on
improving the lives of cancer patients through the discovery,
development, and commercialization of transformative targeted
therapies. Theseus is working to outsmart cancer resistance by
developing pan-variant tyrosine kinase inhibitors (TKIs) to target
all classes of cancer-causing and resistance mutations that lead to
clinically relevant variants in a particular protein in a given
type of cancer. Theseus is developing THE-349, a fourth-generation,
selective epidermal growth factor receptor (EGFR) inhibitor for
C797X-mediated resistance to first- or later-line osimertinib
treatment in patients with non-small cell lung cancer (NSCLC), a
pan-variant BCR-ABL inhibitor for the treatment of
relapsed/refractory chronic myeloid leukemia (CML) and newly
diagnosed Philadelphia
chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL), and a
next-generation, highly selective, pan-variant KIT inhibitor for
the treatment of early-line GIST. For more information, visit
www.theseusrx.com.
Investor Contacts
Josh
Rappaport
Stern Investor Relations
212-362-1200
josh.rappaport@sternir.com
View original
content:https://www.prnewswire.com/news-releases/theseus-pharmaceuticals-to-participate-in-the-stifel-2023-healthcare-conference-301980328.html
SOURCE Theseus Pharmaceuticals